The product has been developed by US Finch Therapeutics Co., and Takeda has obtained a global exclusive license. Applications are in ulcerative colitis and other diseases.
Takeda news release, April 6, 2017
Takeda introduces living bacteria cocktail for treatment of inflammatory bowel disease